Caris Life Sciences, Inc. (NASDAQ: CAI) — Perfil da empresa, notícias e dados financeiros
Caris Life Sciences, Inc.
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. is a precision oncology and molecular diagnostics company that develops and commercializes advanced biotechnology solutions to personalize cancer care. The company performs comprehensive molecular profiling by analyzing DNA, RNA, and proteins using whole exome and whole transcriptome sequencing across tumor tissue and blood samples. Its multi-omic platform generates detailed biomarker data to assist oncologists in treatment selection, risk stratification, and patient monitoring. Additionally, the business maintains a large multimodal database linking genomic profiles with clinical outcomes, providing biopharma partners with data analytics, target discovery, and clinical trial matching services.
Resumo
Operações
Produtos e/ou serviços de Caris Life Sciences, Inc.
- Tissue Molecular Profiling: Comprehensive tissue-based molecular profiling analyzes over 23,000 genes via whole exome and whole transcriptomic sequencing from tumor biopsies. The service evaluates DNA, RNA, and protein biomarkers to guide personalized oncological treatment selection and identify therapeutic targets.
- Liquid Biopsy and Blood Profiling: Non-invasive blood-based molecular profiling assays analyze plasma and circulating cellular fractions across the entire genome. These diagnostic tests enable multi-cancer early detection, minimal residual disease monitoring, and therapeutic selection when tissue samples are unavailable or insufficient for analysis.
- Artificial Intelligence Diagnostics: Machine learning algorithms and computational pathology tools evaluate digitized histological slides and molecular data to predict disease recurrence risk, therapy response, and patient outcomes without requiring additional genomic sequencing steps for early-stage cancer management.
- Biopharma Research Services: Specialized commercialization, target discovery, and clinical trial matching services assist pharmaceutical and biotechnology companies. These capabilities integrate molecular insights and clinical research to accelerate the development and patient recruitment for targeted oncology therapeutic candidates.
- Multimodal Health Data: A vast repository combining genomic, transcriptomic, and proteomic data with real-world clinical outcomes from more than 845,000 matched patient cases supports biomedical research, biomarker validation, target identification, and population-level health insights for oncology.
- International Clinical Diagnostics: Proprietary molecular profiling tests and hybrid tissue-and-liquid assays are supplied to healthcare providers globally through specialized international distributors and clinical laboratory partnerships outside the primary domestic market to expand patient access to targeted medicine.
equipe executiva do Caris Life Sciences, Inc.
- David Dean HalbertChairman, CEO & Founder
- Brian J. BrilleExecutive Vice Chairman & Executive VP
- David SpetzlerPresident
- J. Russel DentonSenior VP, General Counsel & Secretary
- Luke PowerSenior VP, CFO & Chief Accounting Officer
- Jon Mark HarmonSenior VP & Chief Operations Officer
- Valeriy DomenyukSenior VP & CTO
- Milan RadovichSenior VP & Chief Scientific Officer
- Jeremy O'BrienSenior VP of HR & Chief Compliance Officer
- Narendra ChokshiSenior Vice President of Corporate Development
Principais indicadores financeiros
Resultados divulgados pela Caris Life Sciences, Inc., em USD.
- Cap. de mercado
- 10 bi
- Receita (TTM)
- 989,6 mi
- P/L
- 21.0
- LPA (diluído, TTM)
- 1.7
- Dividend yield
- —
- Margem de lucro
- 10.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 812 mi | 45,1 mi | -538 mi | |
| 412,3 mi | -257,1 mi | -281,9 mi | |
| 306,1 mi | -319,6 mi | -341,4 mi | |
| 258,5 mi | -315,8 mi | -320,8 mi |